Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial
Obermayer A, Tripolt NJ, Pferschy PN, Kojzar H, Aziz F, Müller A, Schauer M, Oulhaj A, Aberer F, Sourij C, Habisch H, Madl T, Pieber T, Obermayer-Pietsch B, Stadlbauer V, Sourij H
Diabetes care · 73 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- Austrian Science Fund
- Government
- Austrian Science Fund FWF
- Grants
- Austrian Science Fund (KLI 851‐B)
Based on 2 listed funder(s).
Publication
- Published
- 2022-12-12 · Diabetes Care · vol. 46 · issue 2 · pp. 463–468
- Publisher
- American Diabetes Association
- Cited
- 111 citations · more than 99% of similar papers · 10.6× the field average
- Impact
- Top 10% most cited in its field
- References
- 17 works
- Access
- Open access (repository copy)
- Research areas
- Dietary Effects on Health · Diet and metabolism studies · Genetics, Aging, and Longevity in Model Organisms
- Keywords
- Medicine, Glycemic, Type 2 diabetes, Diabetes mellitus, Hypoglycemia, Randomized controlled trial, Insulin, Weight loss, Internal medicine, Obesity, Endocrinology
- MeSH
- humans, diabetes mellitus, type 2, insulin, blood glucose, hypoglycemic agents, blood glucose self-monitoring, glycated hemoglobin, intermittent fasting
16 authors
From AT, AE
- Anna Maria ObermayerMedical University of Graz
- Norbert Joachim TripoltMedical University of Graz
- Peter N. PferschyMedical University of Graz; Center For Biomarker Research In Medicine
- Harald KojzarMedical University of Graz
- Faisal AzizMedical University of Graz
- Alexander MüllerMedical University of Graz
Abstract
Objective
To investigate the safety and feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes.
Research design and methods
Forty-six people were randomized to an IF or control group. Dietary counseling and continuous glucose monitoring was provided. Coprimary end points were the change in HbA1c from baseline to 12 weeks and a composite end point (weight reduction ≥2%, insulin dose reduction ≥10%, and HbA1c reduction ≥3 mmol/mol).
Results
The IF group showed a significant HbA1c reduction (-7.3 ± 12.0 mmol/mol) compared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012). The coprimary end point was achieved by 8 people in the IF and none in the control group (P < 0.001). No severe hypoglycemia occurred.
Conclusions
IF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.